Kate Therapeutics is a patient-focused biotechnology company developing AAV-based gene therapies to treat genetically defined muscle and heart diseases. Kate Therapeutics applies novel technology platforms that directly address key limitations of current gene therapies, including tissue-specific delivery, liver detargeting, and gene regulation.

Kate Therapeutics

Kate Therapeutics (KateTx) is a patient-focused biotechnology company developing adeno-associated virus (AAV)-based gene therapies to treat genetically defined muscle and heart diseases. The company is applying novel technology platforms that directly address the key limitations of current gene therapies, including tissue-specific delivery and gene regulation. These breakthroughs have the potential to improve the efficacy and safety of gene therapies and enable the pursuit of a broader set of targets that are otherwise difficult to drug with current technologies.

Viewport Meta

IPhone / Mobile Compatible

Google Tag Manager

Apple Mobile Web Clips Icon

HSTS

Google Font API

Google Analytics

WordPress

Global Site Tag

Cloudflare CDN

Senior Accounting Manager

Fay Naea

Operations

Veronica Gutierrez

Principal Scientist

Brian Ferguson

Engineering

Caroline Dang

Chady Hakim

Head of Information Technology

David Donalson

Delayne Di Gangi

Graham Salmun

Chief Business Officer

Gurpreet Ratra

Harvir Grewal

Clare Ozawa

Sharif Tabebordbar

Co-Founder and Chief Scientific Officer

Mark Fielden

Co-Founder, Senior Vice President of Nonclinical Development

Kevin Forrest

Chief Executive Officer and Co-Founder

Beth Seidenberg

Chair of Board

West Coast Acquired Companies With Less Than $1B in Revenue

Companies With Fewer Than 100 Employees (Top 10K)

California Companies With Less Than $1B in Revenue (Top 10K)

Western US Companies With Less Than $1B in Revenue (Top 10K)

Kate Therapeutics is a patient-focused biotechnology company developing AAV-based gene therapies to treat genetically defined muscle and heart diseases.

Series B - Kate Therapeutics

Versant Ventures

Westlake Village BioPartners

Series A - Kate Therapeutics

San Diego

California

United States

North America

Kate Therapeutics Unveils Platform and Pipeline Progress at American Society of Gene & Cell Therapy 2024 Annual ...

Kate Therapeutics reports on DMD gene therapy candidate

Kate Therapeutics on LinkedIn: #katetherapeutics #genetherapy #duchennemusculardystrophy #dmd #asgct2024…

MyoAAV capsids Archives - GEN

ASGCT 2024: Kate Therapeutics Unveils Gene Therapy Platform and Product Pipeline Progress

Kate Therapeutics Unveils Platform and Pipeline Progress at American Society of Gene & Cell Therapy 2024 Annual Meeting

A technology platform for evolving AAV capsid variants for targeted gene delivery to specific tissues.

A class of muscle-tropic capsids developed for enhanced delivery to skeletal and cardiac tissues.

Technologies for improving the regulation, targeting, and safety of gene therapy cargoes.

AAV-based gene therapies aimed at treating genetically defined muscle and heart conditions.

Egypt

Africa

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Aug 8, 2024 7:48 PM	39389115
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 22, 2024 7:44 AM	f8659f60
crunchbase profile	general	Nov 22, 2024 3:33 PM	fd5433a9
li profile	general	Aug 8, 2024 7:48 PM	92f92844
translate crunchbase fundingrounds	general	Nov 22, 2024 7:00 PM	bba365b3
peers	general	Aug 8, 2024 7:48 PM	61cb4df2
news basic	general	Aug 8, 2024 7:48 PM	9d87a9c5
bundesanzeiger	filings
financials download nd	financials
private financials	financials

KATE

COM:KATETHERAPEUTICS

Kate Therapeutics